Select Page

South Delhi Pharma, New Delhi, India

Imatinib

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

Contents: Imatinib
Form: Tablets/Capsules
Strength: 100 mg & 400 mg
Available as : 100 mg & 400 mg tablets or capsules.
Manufactured By: Cipla

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Imatinib, sold under the brand names Gleevec among others, is a medication used to treat cancer.Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome.

2 reviews for Imatinib

  1. click here for more info

    I saw a lot of website but I believe this one has something extra in it in it

    https://shannontaxi.eu

  2. hire a hacker online

    We stumbled over here different page and thought I might as well check things out. I like what I see so now i am following you. Look forward to exploring your web page again.

    https://www.keystroke.group/

Add a review

Your email address will not be published.